Popular
BlogNEW
CompaniesNEW
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Roche Pharmaceutical Development and Sales Overview slide image

Roche Pharmaceutical Development and Sales Overview

PRED immunology and ophthalmology development programs Molecule Indication Status Roche CT Identifier Phase # of patients Immunology selnoflast (NLRP3i, RG6418) Chronic obstructive pulmonary disease lb 102 FPI Q2 2022 Ophthalmology DME, UME | 90 FPI Q3 2019 || ~210 FPI Q4 2021 Anti-IL-6 (RG6179) DME FPI Q4 2020 FPI Q2 2020 DOVETAIL NCT05151744 (BARDENAS) NCT05151731 (ALLUVIUM) NCT04567303 NCT04265261 (CANBERRA) || ~360 FPI Q4 2021 VEGF-Ang2 DutaFab (RG6120) nAMD 200 CB2 receptor agonist (RG7774) DR || = 135 134
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube